ArticleInternational journal of molecular sciences2022

A Novel Triple-Action Inhibitor Targeting B-Cell Receptor Signaling and BRD4 Demonstrates Preclinical Activity in Chronic Lymphocytic Leukemia.

Audrey L Smith et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.